Lv1
40 积分 2022-08-18 加入
Comparative transcriptome profile of mouse macrophages treated with the RhoA/Rock pathway inhibitors Y27632, Fingolimod (Gilenya), and Rezurock (Belumosudil, SLx-2119)
1个月前
已完结
Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP
2个月前
已完结
Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults
2个月前
已完结
Organ Responses, Survival, and Safety of Belumosudil in Chronic Graft‐Versus‐Host Disease: A Systematic Review and Meta‐Analysis
2个月前
已关闭
Nutritional Status of Hematological Patients before Hematopoietic Stem Cell Transplantation and in Early Posttransplantation Period
3个月前
已完结
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
7个月前
已完结
Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
7个月前
已完结
A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China
7个月前
已完结
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
10个月前
已完结
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
10个月前
已完结
皖公网安备34019202002308
